{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:14:57Z","timestamp":1789564497287,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020953","name":"Taiwan Centers for Disease Control","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jmii.2024.08.002","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T01:35:36Z","timestamp":1723167336000},"page":"791-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-8414","authenticated-orcid":false,"given":"Chou-Jui","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Tien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-4693","authenticated-orcid":false,"given":"Jen-Jyh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-2490","authenticated-orcid":false,"given":"Chen-Yuan","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2024.08.002_bib1","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib4","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib7","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2024.08.002_bib8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib9","first-page":"1","article-title":"Active tuberculosis drug-safety monitoring and management (aDSM)","volume":"28","year":"2015","journal-title":"Framework for implementation"},{"key":"10.1016\/j.jmii.2024.08.002_bib10","first-page":"1","article-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis","volume":"6","year":"2013","journal-title":"Interim policy guidance"},{"key":"10.1016\/j.jmii.2024.08.002_bib11","first-page":"1","volume":"23","year":"2014"},{"key":"10.1016\/j.jmii.2024.08.002_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00537-2018","article-title":"QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study","volume":"52","author":"Guglielmetti","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib16","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.jmii.2024.08.002_bib17","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-Induced arrhythmias: a scientific statement from the American heart association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jmii.2024.08.002_bib18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1183\/13993003.01552-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. From the authors","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01386-2018","article-title":"Clofazimine does not lead to significant QT interval prolongation: a multicentre study","volume":"52","author":"Zweijpfenning","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.5588\/ijtld.15.0541","article-title":"Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis","volume":"19","author":"Gupta","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab413","article-title":"QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1149","key":"10.1016\/j.jmii.2024.08.002_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib24","article-title":"Impact of universal drug susceptibility testing and effective management of multidrug-resistant tuberculosis in Taiwan","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jmii.2024.08.002_bib25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-Induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.08.002_bib26","series-title":"Center for biologics evaluation and research (CBER). Guidance for industry. E14 clinical evaluation of QT\/QTc. Interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","year":"2005"},{"key":"10.1016\/j.jmii.2024.08.002_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2024.08.002_bib28","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study","volume":"73","author":"Brust","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jmii.2024.08.002_bib29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","article-title":"Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review","volume":"17","author":"Khan","year":"2018","journal-title":"Expet Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.jmii.2024.08.002_bib30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/cid\/cis664","article-title":"Fluoroquinolones and the risk of serious arrhythmia: a population-based study","volume":"55","author":"Lapi","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2024.08.002_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciu914","article-title":"Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and \u03b2-Lactam\/\u03b2-Lactamase inhibitors: a Taiwanese nationwide study","volume":"60","author":"Chou","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2024.08.002_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","article-title":"Effects of three fluoroquinolones on QT interval in healthy adults after single doses","volume":"73","author":"Noel","year":"2003","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jmii.2024.08.002_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2021.11.037","article-title":"High-dose gatifloxacin-based shorter treatment regimens for MDR\/RR-TB","volume":"115","author":"Nie","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jmii.2024.08.002_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01834-16","article-title":"Effect on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis","volume":"61","author":"Olliaro","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2024.08.002_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02687-20","article-title":"Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2024.08.002_bib36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1183\/13993003.01207-2016","article-title":"Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine","volume":"48","author":"Wallis","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jmii.2024.08.002_bib37","first-page":"63","article-title":"Clofazimine induced cardiotoxicity--a case report","volume":"66","author":"Choudhri","year":"1995","journal-title":"Lepr Rev"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:53:15Z","timestamp":1732629195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118224001464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1684118224001464"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2024.08.002","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2024.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}